Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells
- PMID: 11375323
- DOI: 10.2337/diabetes.50.6.1244
Protein kinase C (PKC)-alpha activation inhibits PKC-zeta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells
Retraction in
-
Statement of Retraction. Gerolama Condorelli, Giovanni Vigliotta, Alessandra Trencia, Maria Alessandra Maitan, Matilde Caruso, Claudia Miele, Francesco Oriente, Stefania Santopietro, Pietro Formisano, and Francesco Beguinot. Protein Kinase C (PKC)-α Activation Inhibits PKC-ζ and Mediates the Action of PED/PEA-15 on Glucose Transport in the L6 Skeletal Muscle Cells. Diabetes 2001;50:1244-1252. DOI: 10.2337/diabetes.50.6.1244. PMID: 11375323.Diabetes. 2019 Feb;68(2):464-465. doi: 10.2337/db19-rt02b. Diabetes. 2019. PMID: 30816852 Free PMC article. No abstract available.
Expression of concern in
-
Expression of Concern. Protein Kinase C (PKC)-α Activation Inhibits PKC-ζ and Mediates the Action of PED/PEA-15 on Glucose Transport in the L6 Skeletal Muscle Cells. Diabetes 2001;50:1244-1252. DOI: https://doi.org/10.2337/diabetes.50.6.1244. PMID: 11375323.Diabetes. 2017 Nov 6;67(2):345-6. doi: 10.2337/db17-ec2017b. Online ahead of print. Diabetes. 2017. PMID: 29109245 Free PMC article. No abstract available.
Abstract
Overexpression of the PED/PEA-15 protein in muscle and adipose cells increases glucose transport and impairs further insulin induction. Like glucose transport, protein kinase C (PKC)-alpha and -beta are also constitutively activated and are not further stimulatable by insulin in L6 skeletal muscle cells overexpressing PED (L6(PED)). PKC-zeta features no basal change but completely loses insulin sensitivity in L6(PED). In these cells, blockage of PKC-alpha and -beta additively returns 2-deoxy-D-glucose (2-DG) uptake to the levels of cells expressing only endogenous PED (L6(WT)). Blockage of PKC-alpha and -beta also restores insulin activation of PKC-zeta in L6(PED) cells, with that of PKC-alpha sixfold more effective than PKC-beta. Similar effects on 2-DG uptake and PKC-zeta were also achieved by 50-fold overexpression of PKC-zeta in L6(PED). In L6(WT), fivefold overexpression of PKC-alpha or -beta increases basal 2-DG uptake and impairs further insulin induction with no effect on insulin receptor or insulin receptor substrate phosphorylation. In these cells, overexpression of PKC-alpha blocks insulin induction of PKC-zeta activity. PKC-beta is 10-fold less effective than PKC-alpha in inhibiting PKC-zeta stimulation. Expression of the dominant-negative K(281)-->W PKC-zeta mutant simultaneously inhibits insulin activation of PKC-zeta and 2-DG uptake in the L6(WT) cells. We conclude that activation of classic PKCs, mainly PKC-alpha, inhibits PKC-zeta and may mediate the action of PED on glucose uptake in L6 skeletal muscle cells.
Similar articles
-
Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance.J Cell Physiol. 2012 Apr;227(4):1485-92. doi: 10.1002/jcp.22864. J Cell Physiol. 2012. PMID: 21618539 Free PMC article.
-
Activation of protein kinase C zeta induces serine phosphorylation of VAMP2 in the GLUT4 compartment and increases glucose transport in skeletal muscle.Mol Cell Biol. 2001 Nov;21(22):7852-61. doi: 10.1128/MCB.21.22.7852-7861.2001. Mol Cell Biol. 2001. PMID: 11604519 Free PMC article.
-
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus.EMBO J. 1998 Jul 15;17(14):3858-66. doi: 10.1093/emboj/17.14.3858. EMBO J. 1998. PMID: 9670003 Free PMC article.
-
Evidence for involvement of protein kinase C (PKC)-zeta and noninvolvement of diacylglycerol-sensitive PKCs in insulin-stimulated glucose transport in L6 myotubes.Endocrinology. 1997 Nov;138(11):4721-31. doi: 10.1210/endo.138.11.5473. Endocrinology. 1997. PMID: 9348199
-
Activation of protein kinase C (alpha, beta, and zeta) by insulin in 3T3/L1 cells. Transfection studies suggest a role for PKC-zeta in glucose transport.J Biol Chem. 1997 Jan 24;272(4):2551-8. doi: 10.1074/jbc.272.4.2551. J Biol Chem. 1997. PMID: 8999972
Cited by
-
Validation of mouse phosphoprotein enriched in astrocyte 15 (mPEA15) expressing transgenic pig as a potential model in diabetes translational research.3 Biotech. 2020 Feb;10(2):34. doi: 10.1007/s13205-019-2021-0. Epub 2020 Jan 7. 3 Biotech. 2020. PMID: 31988828 Free PMC article.
-
Mammalian phospholipase D: Function, and therapeutics.Prog Lipid Res. 2020 Apr;78:101018. doi: 10.1016/j.plipres.2019.101018. Epub 2019 Dec 9. Prog Lipid Res. 2020. PMID: 31830503 Free PMC article. Review.
-
PEA-15 C-Terminal Tail Allosterically Modulates Death-Effector Domain Conformation and Facilitates Protein-Protein Interactions.Int J Mol Sci. 2019 Jul 7;20(13):3335. doi: 10.3390/ijms20133335. Int J Mol Sci. 2019. PMID: 31284641 Free PMC article.
-
A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease.Nucleic Acids Res. 2018 Sep 6;46(15):7772-7792. doi: 10.1093/nar/gky570. Nucleic Acids Res. 2018. PMID: 29986096 Free PMC article.
-
The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.J Transl Med. 2016 Jul 30;14(1):229. doi: 10.1186/s12967-016-0985-7. J Transl Med. 2016. PMID: 27473212 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources